Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 8/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 1.00 |
| ▸ | NQO2 | P16083 | 6/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.77 |
| ▸ | ABL1 | P00519 | 4/20 | 0.77 |
| ▸ | BCR | P11274 | 4/20 | 0.77 |
| ▸ | TTR | P02766 | 3/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.77 |
| ▸ | ESR1 | P03372 | 2/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.77 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.77 |
| ▸ | TUBB | P07437 | 1/20 | 0.77 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.77 |
| ▸ | AHR | P35869 | 1/20 | 0.77 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.77 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.77 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.77 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743363 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| SCHEMBL16362233 | 0.88 | CYP1A1 (0.77) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| 8Z-3,4',5-Trimethoxystilbene SCHEMBL1006207 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| Trismethoxyresveratrol SCHEMBL918740 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| Trismethoxyresveratrol SCHEMBL918739 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| SCHEMBL5784563 | 0.87 | CYP1A1 (0.76) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| SCHEMBL13841258 | 0.87 | CYP1A1 (0.76) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| SCHEMBL5784566 | 0.87 | CYP1A1 (0.76) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| 3,5-O-Dimethylpinosylvin SCHEMBL918727 | 0.86 | KDM4E (0.79) | CYP1A1CYP1B1NQO2CYP1A2ABL1 | |
| 3,5-O-Dimethylpinosylvin SCHEMBL918726 | 0.86 | KDM4E (0.79) | CYP1A1CYP1B1NQO2CYP1A2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313010-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | Szekeres, Thomas (AT) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200086-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2022-09-29 | — | — | WO | claimed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | claimed |
| US-20240166587-A1 | SARS-CoV-2 inhibitors - artificial compounds | SZEKERES THOMAS (AT) | 2024-05-23 | — | — | US | disclosed |
| EP-4313010-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | Szekeres, Thomas (AT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200086-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2022-09-29 | — | — | WO | disclosed |
| US-9187591-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9127115-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-09-08 | — | — | US | disclosed |
| US-9051414-B1 | Polyphenols and high-performance resins from syringaldehyde | The United States of America as Represented by the Secretary of he Navy (US) | 2015-06-09 | — | — | US | disclosed |
| US-9018314-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-04-28 | — | — | US | disclosed |
| US-8993689-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8921614-B1 | Selective deoxygenation of hydroxybenzaldehydes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8835659-B2 | Polysubstituted benzofurans and medicinal applications thereof | IKERCHEM, S.L. (ES) | 2014-09-16 | — | — | US | disclosed |
| US-20130217730-A1 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF | IKERCHEM, S.L. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2388255-A1 | Polysubstituted benzofurans and medicinal applications thereof | Ikerchem, S.L. (ES) | 2011-11-23 | — | — | EP | disclosed |
| US-8038466-B1 | Power receptacle with enlarged heat dissipation path formed on mating face and power connector assembly thereof | ALLTOP ELECTRONICS (SUZHOU) CO., LTD (CN) | 2011-10-18 | — | — | US | disclosed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | disclosed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166587-A1 | SARS-CoV-2 inhibitors - artificial compounds | ACE2, ACE, FURIN | CYP1A1 281/4885CYP1B1 622/4885NQO2 645/4885 |
| US-20130217730-A1 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF | AGER, TFEB, FPGS | CYP1A1 349/4885CYP1B1 107/4885NQO2 324/4885 |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | PTGS2, PTGS1, PTGER2 | CYP1A1 371/4885CYP1B1 275/4885NQO2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.